PARP1 binding proteinGenealiases: AROM · C12orf48 · PARI
Q-omics provides the consensus-scored PARPBP profile across patient tissues and cancer cell-line models. PARPBP expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PARPBP is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, PARPBP RNA expression shows 28,030 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, LUAD, and LSCC as cancer lineages where PARPBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARPBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARPBP survival associations across molecular data types. PARPBP RNA expression shows survival associations in the most cancer types (30), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARPBP RNA expression–survival associations across cancer types. High PARPBP expression shows unfavorable associations in ACC, KIRP, MESO, LIHC, UVM and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PARPBP RNA expression.
This table summarizes PARPBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PARPBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARPBP shows higher tumor expression in LUAD, BLCA, KIRP, LUSC, STAD and COAD. The LUAD box plot shows higher PARPBP RNA expression in tumor versus normal tissue (log2 FC = +2.525, t-test p < 0.001).
This table shows molecular features associated with PARPBP in patient tissues and cancer cell lines. In patient samples, PARPBP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PARPBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
